nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

19.07.2022 | Research Highlights

Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting

verfasst von: Sepideh Gholami, Mustafa Abidalhassan, May Cho, Anwaar Saeed, Flavio G. Rocha

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022.

Methods

We reviewed the abstracts presented at ASCO GI 2022. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on clinical practice.

Results and Conclusion

This year’s hybrid ASCO-GI symposium (2022) introduced many promising new treatment strategies in GI oncology, with several changes in clinical practice for patients with advanced hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic colorectal cancer (CRC).

Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clinic Oncol. 2022;40(4_suppl):238–238. https://doi.org/10.1200/JCO.2022.40.4_suppl.238.

Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/s0140-6736(21)01234-4.CrossRefPubMed

Metges J-P, Kato K, Sun J-M, et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. J Clinic Oncol. 2022;40(4_suppl):241–241. https://doi.org/10.1200/JCO.2022.40.4_suppl.241.

Shitara K, Janjigian YY, Moehler MH, et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649. J Clin Oncol. 2022;40(4_suppl):240–240. https://doi.org/10.1200/JCO.2022.40.4_suppl.240.CrossRef

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/s0140-6736(21)00797-2.CrossRefPubMedPubMedCentral

Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clinic Oncol. 2022;40(4_suppl):379–379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379.

Oh D-Y, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clinic Oncol. 2022;40(4_suppl):378–378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.

Hammel P, El-Hariry I, Macarulla T, et al. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441). J Clinic Oncol. 2022;40(4_suppl):518-518. https://doi.org/10.1200/JCO.2022.40.4_suppl.518.

Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clinic Oncol. 2022;40(4_suppl):519–519. https://doi.org/10.1200/JCO.2022.40.4_suppl.519.

10.

Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J Clinic Oncol. 2022;40(4_suppl):12–12. https://doi.org/10.1200/JCO.2022.40.4_suppl.012.

11.

Lumish MA, Cohen JL, Stadler ZK, et al. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. J Clinic Oncol. 2022;40(4_suppl):16–16. https://doi.org/10.1200/JCO.2022.40.4_suppl.016.

12.

Saeed A, Park R, Dai J, et al. Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. J Clinic Oncol. 2022;40(4_suppl):135–135. https://doi.org/10.1200/JCO.2022.40.4_suppl.135.

13.

Abrams TA, Kazmi SMA, Winer IS, et al. A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. J Clinic Oncol. 2022;40(4_suppl):121–121. https://doi.org/10.1200/JCO.2022.40.4_suppl.121.

14.

Kotaka M, Shirasu H, Watanabe J, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clinic Oncol. 2022;40(4_suppl):9–9. https://doi.org/10.1200/JCO.2022.40.4_suppl.009.

Titel: Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting
verfasst von: Sepideh Gholami
Mustafa Abidalhassan
May Cho
Anwaar Saeed
Flavio G. Rocha
Publikationsdatum: 19.07.2022
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2023
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-022-00849-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting

Abstract

Purpose

Methods

Results and Conclusion

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results and Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?

Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial

The Clinical Impact of Apical Lymph Node Metastasis of Colorectal Cancer After Curative Resection

Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment

Prevalence of Gastric Preneoplastic Lesions in First-Degree Relatives of Patients with Gastric Cancer: a Cross-Sectional Study

Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie